<?xml version='1.0' encoding='utf-8'?>
<document id="22300021"><sentence text="An insight into the interaction between clopidogrel and proton pump inhibitors."><entity charOffset="40-51" id="DDI-PubMed.22300021.s1.e0" text="clopidogrel" /></sentence><sentence text="Platelet activation and aggregation have been established as pivotal elements in the pathogenesis of atherosclerotic and ischemic diseases, including acute coronary syndromes" /><sentence text=" The difficulty of achieving optimal platelet inhibition remains a major constraint following dual-antiplatelet therapy, which can lead to a diminished response following initiation of clopidogrel therapy"><entity charOffset="185-196" id="DDI-PubMed.22300021.s3.e0" text="clopidogrel" /></sentence><sentence text=" Though the absolute mechanisms underlying clopidogrel resistance are controversial, a variety of responsible factors are recognized"><entity charOffset="43-54" id="DDI-PubMed.22300021.s4.e0" text="clopidogrel" /></sentence><sentence text=" Clopidogrel, being a prodrug, requires conversion to an active metabolite for its activity"><entity charOffset="1-12" id="DDI-PubMed.22300021.s5.e0" text="Clopidogrel" /></sentence><sentence text=" This metabolism involves various cytochrome P450 (CYP) enzymes at different steps, and it is hypothesized that competitive inhibition of CYPs may contribute to clopidogrel resistance"><entity charOffset="161-172" id="DDI-PubMed.22300021.s6.e0" text="clopidogrel" /></sentence><sentence text=" Proton pump inhibitors (PPIs) are competitive inhibitors of CYPs that can attenuate the antiplatelet activity of clopidogrel, and this can lead to clopidogrel resistance"><entity charOffset="114-125" id="DDI-PubMed.22300021.s7.e0" text="clopidogrel" /><entity charOffset="148-159" id="DDI-PubMed.22300021.s7.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.22300021.s7.e0" e2="DDI-PubMed.22300021.s7.e0" /><pair ddi="false" e1="DDI-PubMed.22300021.s7.e0" e2="DDI-PubMed.22300021.s7.e1" /></sentence><sentence text=" Available data from different clinical studies have postulated the possibility of a drug-drug interaction between clopidogrel and PPIs"><entity charOffset="115-126" id="DDI-PubMed.22300021.s8.e0" text="clopidogrel" /></sentence><sentence text=" PPIs differ somewhat in their pharmacokinetic properties like bioavaibility and affinity for CYP2C19" /><sentence text=" However it is not clear whether the proposed drug interaction of PPI with clopidogrel is same with all PPIs (i"><entity charOffset="75-86" id="DDI-PubMed.22300021.s10.e0" text="clopidogrel" /></sentence><sentence text="e" /><sentence text=", a class effect) or it is limited to a subset of PPIs (i" /><sentence text="e" /><sentence text=", a drug effect)" /><sentence text=" This interaction needs further assessment with well designed prospective clinical trials, before any change in clinical practice should be considered" /><sentence text=" In this review, we attempt to evaluate the available evidence exploring drug interactions with PPIs as the underlying mechanism for the reduced antiplatelet effect of clopidogrel"><entity charOffset="168-179" id="DDI-PubMed.22300021.s16.e0" text="clopidogrel" /></sentence><sentence text="" /></document>